Summit Therapeutics Inc. (SMMT)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

17.59 on 9 Oct 2026

8 buys0 sales at will0 planned sales

Fiscal year 2024, ended 31 Dec 2024, as filed

Revenue

$0.00

Net income

$221.32M

Free cash flow

$142.25M

Return on equity

-56.9%

Return on capital

-45.9%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
12 Jun 2026	Zanganeh Mahkam Co-Chief Executive Officer	Bought	$49.99M	0.7%
12 Jun 2026	DUGGAN ROBERT W Co-Chief Executive Officer	Bought	$49.99M	0.7%
4 Jun 2026	DUGGAN ROBERT W Co-Chief Executive Officer	Bought	$1.46M	0.4%
4 Jun 2026	Zanganeh Mahkam Co-Chief Executive Officer	Bought	$1.46M	0.4%
4 Jun 2026	Soni Manmeet Singh COO and CFO	Bought	$722.25K	1.6%
21 Oct 2025	Xia Yu Director	Bought	$10.00M	1.7%

37out of 100

Profitability 4

Financial strength 63

Growth 0

Insiders 100

Strongest on insiders (100), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$114.62M

8 buys, 4 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan